Cancer cachexia is a systemic hypoanabolic and catabolic syndrome that diminishes the
quality of life of cancer patients, decreases the efficiency of therapeutic strategies and …

Numerous health problems including acute critical illness, cancer, diseases associated with
chronic inflammation, and neurological disorders often result in skeletal muscle weakness …

Chronic inflammation is a hallmark of cancer cachexia in both patients and preclinical
models. Cachexia is prevalent in roughly 80% of cancer patients and accounts for up to 20 …

IL-6 remains a promising therapeutic strategy for attenuating cachexia progression with
many types of cancer. However, improvement of this treatment will require a better …

Cancer cachexia is a complex multi‐organ catabolic syndrome that reduces mobility,
increases fatigue, decreases the efficiency of therapeutic strategies, diminishes the quality of …

Cancer cachexia is a multifactorial syndrome characterized by a progressive loss of skeletal
muscle mass associated with significant functional impairment. In addition to a loss of …

While skeletal muscle mass is an established primary outcome related to understanding
cancer cachexia mechanisms, considerable gaps exist in our understanding of muscle …

Cancer cachexia is a complicated disorder of extreme, progressive skeletal muscle wasting.
It is directed by metabolic alterations and systemic inflammation dysregulation. Numerous …

Cachexia, the unintentional loss of body weight, is prevalent in many cancer types, and the
associated skeletal muscle mass depletion increases patient morbidity and mortality. While …

Purpose Cancer-induced muscle wasting (ie, cancer cachexia, CC) is a common and
devastating syndrome that results in the death of more than 1 in 5 patients. Although …